Key result
Patients with dilated cardiomyopathy had a higher prevalence of autoantibodies against beta 1 adrenoceptors (32% vs 9%) and M2 muscarinic receptors (36% vs 13%) compared to healthy subjects.
Why the study?
Do patients with dilated cardiomyopathy have a higher prevalence of autoantibodies against specific G-protein-coupled cardiovascular receptors compared to healthy subjects?
Case-Control (n=50)
Do patients with dilated cardiomyopathy have a higher prevalence of autoantibodies against specific G-protein-coupled cardiovascular receptors compared to healthy subjects?
Absolute Event Rate: 32% vs 9%
A subgroup of patients with dilated cardiomyopathy possesses a specific spectrum of autoantibodies directed against beta 1 adrenoceptors and M2 muscarinic receptors.
No takes yet. Share an insight, caveat, or question.
Supports autoimmune contribution to dilated cardiomyopathy; leaves open causal role and therapeutic implications.
Matsui et al. (1995) conducted a case-control in Dilated cardiomyopathy (n=50). Enzyme immunoassay for autoantibodies against G-protein-coupled cardiovascular receptors vs. Healthy subjects was evaluated on Prevalence of autoantibodies against the beta 1 adrenoceptor peptide. Patients with dilated cardiomyopathy had a higher prevalence of autoantibodies against beta 1 adrenoceptors (32% vs 9%) and M2 muscarinic receptors (36% vs 13%) compared to healthy subjects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: